Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.755 USD | +8.18% | +2.54% | -42.71% |
05-09 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
05-09 | Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.71% | 438M | |
+25.90% | 44.96B | |
+0.24% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+10.49% | 26.08B | |
-20.95% | 19.03B | |
+6.78% | 12.75B | |
+29.01% | 12.06B | |
-3.78% | 11.75B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine's EDIT-301 Receives US FDA's Regenerative Medicine Advanced Therapy Designation